Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Begoña Comin-Anduix

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Oncotargets and Therapy|April 5, 2016
Tremelimumab: research and clinical developmentBegoña Comin-Anduix, Helena Escuin-Ordinas, Francisco Javier Ibarrondo
Biotechniques|March 17, 2017
Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran dopingMichael T Bethune, Begoña Comin-Anduix, Yu-Hsien Hwang Fu, et al.
Nature Biotechnology|March 5, 2002
Metabolic control analysis in drug discovery and diseaseMarta Cascante, Laszlo G Boros, Begoña Comin-Anduix, et al.
Cells|October 28, 2025
Description of T-Cell and Monocyte Populations in the Circulation of People with HIV Prior to AIDS-NHL DiagnosisLaura E Martínez, Begoña Comin-Anduix, Miriam Güemes-Aragon, et al.
Frontiers in Immunology|September 26, 2024
Characterization of unique B-cell populations in the circulation of people living with HIV prior to non-Hodgkin lymphoma diagnosisLaura E Martínez, Begoña Comin-Anduix, Miriam Güemes-Aragon, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapyPaul C Tumeh, Richard C Koya, Thinle Chodon, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 14, 2010
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responsesRichard C Koya, Stephen Mok, Begoña Comin-Anduix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrationsBegoña Comin-Anduix, Thinle Chodon, Hooman Sazegar, et al.
Cancer Immunology Research|October 6, 2023
Antitumor Immune Responses in B2M-Deficient CancersDavis Y Torrejon, Mildred Galvez, Gabriel Abril-Rodriguez, et al.
Cells|January 21, 2023
Characterization of T Follicular Helper Cells and T Follicular Regulatory Cells in HIV-Infected and Sero-Negative IndividualsBradley Salvatore, Rachel S Resop, Brent R Gordon, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Oncotargets and Therapy|April 5, 2016
Tremelimumab: research and clinical developmentBegoña Comin-Anduix, Helena Escuin-Ordinas, Francisco Javier Ibarrondo
Biotechniques|March 17, 2017
Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran dopingMichael T Bethune, Begoña Comin-Anduix, Yu-Hsien Hwang Fu, et al.
Nature Biotechnology|March 5, 2002
Metabolic control analysis in drug discovery and diseaseMarta Cascante, Laszlo G Boros, Begoña Comin-Anduix, et al.
Cells|October 28, 2025
Description of T-Cell and Monocyte Populations in the Circulation of People with HIV Prior to AIDS-NHL DiagnosisLaura E Martínez, Begoña Comin-Anduix, Miriam Güemes-Aragon, et al.
Frontiers in Immunology|September 26, 2024
Characterization of unique B-cell populations in the circulation of people living with HIV prior to non-Hodgkin lymphoma diagnosisLaura E Martínez, Begoña Comin-Anduix, Miriam Güemes-Aragon, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapyPaul C Tumeh, Richard C Koya, Thinle Chodon, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 14, 2010
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responsesRichard C Koya, Stephen Mok, Begoña Comin-Anduix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrationsBegoña Comin-Anduix, Thinle Chodon, Hooman Sazegar, et al.
Cancer Immunology Research|October 6, 2023
Antitumor Immune Responses in B2M-Deficient CancersDavis Y Torrejon, Mildred Galvez, Gabriel Abril-Rodriguez, et al.
Cells|January 21, 2023
Characterization of T Follicular Helper Cells and T Follicular Regulatory Cells in HIV-Infected and Sero-Negative IndividualsBradley Salvatore, Rachel S Resop, Brent R Gordon, et al.
Pageof 5